Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed surface antigens on tumor cells. The low expression of several tumor-associated antigens (TAA) on normal tissues, however, hinders their safe targeting by CAR T cells due to on-target/off-tumor effects. Using the Multiple Myeloma (MM)-associated CD38 antigen as a model-system, we here present a rational approach for effective and tumor-selective targeting of such TAAs. Using the "light chain exchange" technology, we combined the heavy chains of two high-affinity CD38 antibodies with 176 germline light chains and generated ~124 new antibodies with 10 to >1000-fold lower affinities to CD38. After categorizing them in three distinct affinity classes, we incorporated the single-chain variable fragments of eight antibodies from each class into new CARs. T cells carrying these CD38-CARs were extensively evaluated for their on-tumor/off-tumor cytotoxicity as well as CD38-dependent proliferation and cytokine production. We identified CD38-CAR T cells of ~1000-fold reduced affinity which optimally proliferated, produced Th1 like cytokines and effectively lysed CD38 ++ MM cells but spared CD38 + healthy hematopoietic cells, in vitro and in vivo. Thus, this systematic approach is highly suitable for the generation of optimal CARs for effective and selective targeting of TAAs.
Introduction
Cytotoxic T cells endowed with chimeric antigen receptors (CARs) against surface antigens on tumor cells can induce powerful anti-tumor effects in experimental models and long term remissions in clinical trials. Specifically CAR T cells targeting CD19, an antigen present in B-cell leukemias and lymphomas, have shown impressive clinical results. [1] [2] [3] [4] [5] Hence, CAR T cells are currently considered highly appealing tools for cancer immunotherapy. Ideally the target molecule for CAR T cell therapy should be specifically expressed on tumor cells. Nonetheless, several years of research have identified only a few true tumor-specific surface antigens. Currently most tumor-associated target antigens (TAA) are expressed, albeit at low-to-intermediate levels, also on one or more normal tissues, such as epidermal growth factor receptors (EGFR and ErbB2/Her2), prostate specific membrane antigen (PSMA) or Carcinoembryonic antigen (CEA). 6, 7 Targeting such antigens with CAR T cells raises safety concerns, due to on-target off-tumor toxicities with unpredictable severity. The application of carbonic anhydrase IX-specific CAR T cells in renal cell cancer resulted in liver toxicities 8 and CEAspecific CAR T cells in colon cancer patients induced severe colitis. 9 Additionally, a high antigen load, on tumor and healthy tissues can elicit a significant cytokine response when targeted with highly reactive T cells. 3, 10, 11 Targeting HER2 with CAR T cells caused a fatal cytokine release syndrome (CRS), due to the recognition of low levels of HER2 expressed on the cells of lung epithelium. 12 In a recent preclinical study we have shown that CD38 is a useful target antigen for the treatment of multiple myeloma (MM) and that high affinity CD38-CAR T cells have significant anti-MM function in vitro and in vivo. 13 Although CD38 is expressed at very high levels on all MM cells, it is also present at intermediate levels on several hematopoietic cells, including NK cells, monocytes and a fraction of T cells. As expected, with high affinity CD38-CAR T cells we not only observed strong anti-MM effects, but also noted on-target off-tumor effects against normal hematopoietic cells.
Optimization of the design of the extracellular recognition domain of CARs has been proposed, among others, as an approach in order to enhance the capacity of CAR T cells to discriminate between tumors and normal tissues that express the same antigen in lower levels. Tumor selective effects of CARs have been observed when using single chain variable regions (scFv) of existing low(er) affinity antibodies. [14] [15] [16] Thus, actively decreasing and optimizing the affinity of existing antibodies could allow for minimizing the off-tumor CAR responses, which in fact has been achieved by the introduction of mutations or the replacement of human with murine residues in the scFv domain. [16] [17] [18] [19] Nonetheless, a convenient approach that can be utilized to de novo generation of a large panel of candidate scFvs and methodically selection of those CARs with an optimal target affinity is still lacking.
We here describe a rational and feasible strategy, using CD38 as a model-antigen, for tumor-associated but not entirely tumor-specific antigens. To generate new antibodies binding the same epitope with a broad range of different affinities, we used the light chain exchange technology. [20] [21] [22] [23] Combining the heavy chains of two high-affinity CD38 antibodies with 176 germline light chains allowed the generation of more than a hundred new CD38 antibodies with 10-1000 fold lower affinities to CD38. The panel of candidate scFvs was narrowed down using rational selection criteria based on the desired immunotherapeutic properties of CAR T cells. Systematic in vitro and in vivo analysis of the newly generated CARs revealed that CAR T cells bearing scFvs derived from ±1000-fold lower affinity antibody were tumor selective killers with strong lysis of CD38 ++ MM cells and little or no lysis of CD38 + normal human hematopoietic cells.
Methods

Antibody production by Light chain exchange
Variable heavy-and light chain coding regions were cloned in the pcDNA3.3 (Invitrogen) based vectors p33G1f and p33Kappa respectively. All 352 antibodies were produced under serum-free conditions by individually co-transfecting 2 heavy chains (024 and 028) and 176 germline light chain expression vectors in HEK-293F cells, using 293fectin (Invitrogen), as previously described. 24 A simple, robust and highly efficient transient expression system for producing antibodies. 24 Cell-free supernatants were harvested and antibody concentrations were determined by Octet IgG quantification (Forté Bio).
Bio-layer interferometry
Affinities were measured and ranked using biolayer interferometry on a Octet HTX instrument (ForteBio). Anti-Human IgG Fc Capture biosensors (ForteBio) were loaded for 1000 s with hIgG1
containing different heavy and light chain combinations directed against CD38. After a baseline (100 s) the association (1000 s) and dissociation (1000 s) of the extracellular domain of N-terminally Histagged CD38 (His-CD38,100 nM) in Sample Diluent (ForteBio) was determined. For calculations, the theoretical molecular mass of His-CD38 based on the amino acid sequence was used, i.e. 30.5 kDa.
Experiments were carried out while shaking at 1000 rpm and at 30 °C. Data was analyzed with Data Analysis software v8.0 (ForteBio), using the 1:1 model and a local full fit with 1000 s association time and 250 s dissociation time. Data traces were corrected by subtraction of the average of 4 reference biosensors loaded with IgG1-3003-028 WT and incubated with Sample Diluent only. The Y-axis was aligned to the last 5 s of the baseline, and interstep correction as well as Savitzky-Golay filtering was applied.
Antibody Binding assay
Homogenous binding assays for human CD38 specific antibodies were performed in 1536 well signals were recorded using the Applied Biosystems 8200 Cellular Detection System (ThermoFisher Scientific) with a 50 counts cut-off value applied. Obtained total fluorescence intensity data was processed and visualized using ActivityBase software (IDBS).
Introduction of CD38-specific scFvs in CAR constructs
The selected variable light and heavy chains were amplified using PCR with primers (supplemental table S3) containing homology arms and Gibson assembly (NEB) was used to combine both chains linked with a G 4 S linker. The generated scFvs were cloned into SFG retroviral vector, followed by a CD8a transmembrane domain and the 4-1BB and CD3ζ signaling domains as described in Zhao et al. 25 The CAR constructs were linked by a 2A sequence to a truncated NGFR or dsRed sequence.
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Generation of retroviral particles and transduction of T cells
Phoenix-Ampho packaging cells were transfected with the CAR constructs, gag-pol (pHIT60), and envelope (pCOLT-GALV) vectors (Roche). Two and three days after transfection, cell free supernatants containing retroviral particles were collected and directly used for transduction. 
Cell lines
Unmodified or luciferase (Luc-GFP)-transduced human MM cell lines, UM9 and RPMI8226 were cultured in RPMI-1640 (Invitrogen) + 10% FBS (Invitrogen) + antibiotics (penicillin;10.000 U/ml, streptomycin; 10,000 µg/ml) as described.
13
Cloning, expression and purification of CD38 extracellular domain (sCD38)
A synthetic DNA construct encoding the Honeybee Melittin signal sequence (HMSS) fused to a fragment of the extracellular CD38 domain encoding residues 43-400 was purchased (GeneArt). The HMSS-CD38 DNA was cloned into the pFastBacNKI-LIC-3C-his vector 27 to get pFastBACNKI- 
Detection of CAR expression
The sCD38 Statistical methods. Statistical analyses were performed using Graphpad Prism software 6. In analyses where multiple groups were compared, either a parametric ANOVA or nonparametric
Kruskal-Wallis test were used with subsequent multiple comparison. A p value <0.05 was considered significant.
Results
Generation of lower affinity CD38 antibodies by light chain exchange.
To generate lower affinity CD38 antibodies we applied the light chain exchange technology, in which we combined the heavy chains of high affinity antibodies 028 and 024 (described in patents WO2011154453 and WO2006099875) with 176 random germ line light chains, schematically depicted in figure 1A . One of these two antibodies, 028, was previously used to generate high affinity CD38-CAR T cells. 13 Antibodies with the strongest binding capacity also displayed a detectable biolayer interferometry signal on an Octet HTX instrument, whereby the on-rate (k on ), off-rate (k off ) and affinity constant (K D ) ( Fig. 1D and E) could be determined. As illustrated in figure 1E left panel, the K D values of those antibodies were 10 to 1000 times lower than the K D of the original antibody 028. Based on these data we classified all functional antibodies into three classes: Class A represented antibodies with a similar binding profile to CD38 as the parental (wildtype) antibodies but with ±10-1000 x lower affinity.
Class B antibodies had no detectable affinity by biolayer interferometry but binding to CD38-positive cells/beads, (thus >1000x lower affinity to the original antibody), while the class C antibodies showed solely binding to CD38 positive cells, thus with an affinity even lower than the category B. Sequence similarities and differences in complementary determining regions (CDRs) of these antibodies are illustrated in supplemental table S1. We selected 8 antibodies from each class and generated 24 different CARs using their scFvs. A selection of soluble scFvs were evaluated for unwanted, induced aggregation or impurity, to exclude protein instability as a cause for their altered affinity (supplemental Fig. S1 ). PBMC-derived T cells from a healthy donor were transduced with the selected 24 newly generated CARs.
Anti-Myeloma activity of CD38-CAR T cells with variable affinities.
Since the anti-tumor function of CAR T cells is of primary importance, we first determined the lytic capacity of the newly generated CD38-CAR T cells against the CD38-positive MM cell line UM9.
While CAR T cells generated from class C antibodies did not lyse the UM9 cells at all, T cells transduced with CARs from Class B and A antibodies were capable of lysing MM cells. As predicted, the highest affinity CARs (class A) were better in lysing tumor cells, compared to class B (Fig. 2) .
Interestingly, some T cells transduced with class A antibodies (CARAx T cells) lysed the UM9 cell line as effective as the CAR T cells which were generated from the original 028 antibody (CAR028 T cells) despite their much lower affinity for CD38. On the other hand, all CARs with the 024 variable heavy chain (VH) (CARs 5 -8 in each class) elicited inferior tumor cytotoxicity compared to CARs generated using the VH of the 028 antibody (CARs 1 -4 in each class). Based on these results, 2 of the best CARs from both class A and B were selected (CARA1, A4, B1 and B3) ( Fig. 2 indicated with arrows), and were analyzed for their proliferative capacity cytokine production and on-target off-tumor cytotoxicity to gain more insight into their immunotherapeutic properties.
Cytokine release of lower affinity CAR T cells
The selected CAR T cells were first tested for their CD38-dependent cytokine production after stimulation with MM cell line UM9. All four CAR T cells, similar to the control high affinity CAR028
T cells, produced IFN-γ, IL-2 and TNFα in the presence but not in the absence of CD38+ target (Fig.   3A) . Little or no IL-4, IL-5 or IL-10 (supplemental Fig. S4 ) were produced, thus indicating a typical Th1 cell phenotype. The level of cytokine production showed some association with the CAR affinity for CD38. Importantly however, the level of cytokine secretion by CARA1-and A4-transduced T cells showed no substantial difference from the high affinity CAR028 T cells.
Proliferation and expansion of lower affinity CAR T cells
We have previously showed that high affinity CD38-CAR T cells display a slower growth rate in the first two weeks due to fratricide. After this period they readily expanded, but displayed no CD38 expression on the cell surface. Therefore we also tested the CD38-dependent in vitro proliferative capacity and the immunophenotype of the four candidate CAR T cells after one week of transduction and after weekly stimulations with irradiated UM9 cells (Fig. 3 (Fig. 3C ).
T cells endowed with lower affinity CARs mediate no or minimal off-tumor effects
Since our specific aim was to generate CAR T cells with minimal off-tumor on-target effects by affinity optimization, we finally determined the cytotoxic activity of the four selected CARs towards MM cells as well as normal healthy cells. Although CD38 can be expressed on several tissues, we studied hematopoietic cells as the prominent candidates of off-tumor effects because preliminary immunohistochemistry assays of several normal tissues revealed that the expression of CD38 was the highest in hematopoietic cells (data not shown). lysis for the lowest affinity CARB3. (Fig. 4A top panel) . Importantly, the lysis levels of CARA1 and
CARA4 T cells did not significantly differ from the control CAR028 T cells 14
The lysis of CD38 + fractions of normal B, T, NK cells and monocytes by CARA1, A4, B1 and B3 T cells comprised 84, 24, 23 and 6%, respectively, while the mock T cell mediated background lysis was 7%. Thus except CARA1 T cells, all other candidates showed negligible or no off-target effects on CD38 + fractions of normal hematopoietic cells. When the hematopoietic cells were analyzed regardless of CD38 expression the total hematotoxicity of CARA1, A4, B1 and B3 T cells comprised only 20, 3, 20, 0%, respectively of which 11% was background, mock T cell mediated lysis. In contrast, the off-tumor effect of control CAR028 T cells was substantially higher (90% lysis of CD38 + fraction; 39% lysis regardless of CD38 expression) (Fig. 4 B, C, illustrative flow cytometry plots in 4D). These data indicate that indeed the newly generated low affinity CAR T cells have minimal offtumor effects.
Selection of the best lower affinity CD38-CAR T cells.
Finally, to rationally select the most optimal CAR T cell, we summarized the in vitro data of the candidate CD38-CAR T cells, primarily according their anti-MM cytotoxicity and off-tumor hematopoietic cell toxicity, and secondarily according to cytokine production and proliferative capacity (supplemental table S2). Based on these criteria we excluded CARB3 T cells due to too low anti-tumor reactivity and CARA1 T cells due to too high off-tumor effects (Fig. 5) . The remaining candidates were compared according to the secondary criteria. The CARA4 appeared the best performer since its proliferative capacity and especially the cytokine production was much better than that of CARB1.
The in vivo anti-tumor effects of CARA4 T cells
We then evaluated the in vivo anti-tumor and off-tumor effects of CARA4 T cells and compared these effects with those of CAR028 and mock T cells. To mimic the human MM microenvironment, we used the specific Rag2 -/-γc -/-xenograft murine model, where the luciferase transduced tumor cells are grown in humanized BM like-niches generated by subcutaneous implantation of ceramic scaffolds coated with human bone marrow stromal cells (hu-BMSCs). 29 As illustrated in figure 6A , in the negative control group treated with mock T cells, tumors showed a fast progression. Although not curative, treatment of the tumor-bearing mice either with CAR028 or CARA4 T cells induced a significant and apparently similar anti-tumor effect (Fig. 6A, B) . We did not encounter a tumor escape due to antigen-loss variants since post mortem analyses revealed that all remaining tumor cells in the mice were CD38 + (supplemental Fig. S6 ).
The in vivo on target off-tumor effects of CARA4 T cells
In the in vivo model we observed the maximum anti-tumor effects in the first three weeks (Fig. 6 ). To T cells. The FLI signal from normal hematopoietic progenitors was followed during 3 weeks. Injection of CARA4 T, CAR028 T or mock T cells had no effect on the FLI signal (Fig. 7A ). This observation was confirmed by CAR028 and CARA4 pre-treated CD34 cells, which could still form similar numbers of colonies in a colony forming assay (supplemental Fig. S7 ). Nonetheless, post-mortem analysis, after three weeks revealed in mice treated with CAR028 T cells significantly lower percentages (Fig. 7B ) and total cell numbers (Fig. 7C ) of CD38 + cells within the CD34 + fraction.
Similar results were observed within the more differentiated CD34 -fractions as compared to CARA4
T cell treated animals ( Fig. 7B and C) .
This indicated that CARA4 had no effect on CD34 + progenitor cells or more differentiated hematopoietic cells even if they expressed CD38. In contrast, treatment with CAR028 T cells did not hamper the total FLI signal, mediated toxicity against all CD38 + cells including the progenitor and differentiated cells. Since this could eventually result in defects in the differentiation of some lineages we concluded that CARA4 cells were also better performers in vivo. optimal antibody affinity of 1.1 nM for the same antigen. In our study, we exchanged the antibody light chain while keeping the heavy chain constant, which is suggested to modulate the affinity but not the epitope specificity of an antibody. 30, 31 In contrast to previous studies, in which a limited panel of no more than 8 new scFvs was tested, 15, 16, 19, 34 the light chain exchange technology allowed us to rapidly generate hundreds of new antibodies with a large range of affinities to the CD38 molecule.
Discussion
Thus, we were able to methodically identify the optimal candidate with the desired immunotherapeutic properties whereby a truly tumor-selective cytotoxic activity could be achieved. In fact our results as well as the results of others, [14] [15] [16] 34 indicate that such a systematic approach is necessary because, as mentioned above, there are yet no universal parameters, which could help to predict the optimal antibody/scFv affinity for each epitope and every target antigen. Interestingly, with this technique we could lower the highest antibody affinity of 1.8 nM more than a 1000-fold and still obtain CARs with significant anti-tumor cytotoxicity and minimal off-tumor effects. While we have not tested the affinity of the scFvs to the CD38 antigen, the affinities of the selected antibodies correlated well with the CAR activity.
In order to select the optimal CAR construct we followed a logical approach in which we started with heavy chains of two high affinity antibodies (024 and 028) and extensively characterized the generated new antibodies for their affinity. We then categorized these antibodies into three "affinity groups" and selected 8 representative antibodies from each group, hereby pragmatically decreasing the pool to 24 scFv candidates to construct new CARs. The resulting 24 CAR constructs were first screened according to their anti-tumor cytotoxicity, since this is the most crucial desirable immunotherapeutic function. This approach appeared highly convenient since we could readily eliminate all antibodies within the lowest affinity class. Furthermore, although the candidate antibodies did not show significant affinity differences, the CARs generated from the 024 heavy chain were in general inferior as compared to CARs generated from 028 heavy chain, indicating the importance to start with more than one heavy chain, whenever possible. Although some 024 CARs showed intermediate lysis of MM cells, we continued only with 028-antibody based CARs, as there were already excellent candidates within this category. We extensively evaluated 4 candidates from this group which elicited >50% antitumor cytotoxicity in our in vitro assays. To select the most optimal CAR we thoroughly evaluated their several functional properties such as cytokine secretion, long-term antigen-specific proliferation, immunophenotype, but more importantly their on-target and off-tumor cytotoxicity against primary human samples. We finally selected the CARA4 as the most optimal CAR T cells transduced with this CAR elicited similar anti-MM cytotoxic response like the original CAR028, but without having significant off-tumor toxicity on primary hematopoietic cells. Furthermore their long-term proliferation capacity was also similar to the original high affinity CAR028 T cells and they maintained Th1 cytokine production, which was even better than the other potential candidate CARB1.
To our knowledge this is the first study where CARs bearing scFvs with different antigen affinities are thoroughly tested in vitro and scored for all the above-mentioned properties, which define the immunotherapeutic potency of CAR T cells. Importantly, the capacity of CD38-CARA4 T cells to delay MM tumor growth in a manner similar high affinity CD38-CAR028 T cells was also confirmed in an in vivo murine xenograft model.
To date, most studies investigating the on-target off-tumor effects of CAR T cell therapy make the use of artificial modeling for "healthy cells" using tumor cell lines which express or are transduced to express the target antigen in low levels. 15, 16, 35 Although valuable in several aspects, such an approach is not ideal for evaluating the off-tumor effects of CAR T cells, since several other differences between tumor and healthy cells, especially the differences in susceptibility to cytolysis, are neglected.
Therefore in our approach we always compared primary tumor cells with primary healthy cells, whose relative low proliferation rate may render them more susceptible to cytotoxicity. Moreover, in order to reduce variability and to simulate the in vivo clinical setting as good as possible, we executed all our in vitro testing of tumor cells and the healthy cells side by side, in the same compartment (BM) and at the same time. As it is suggested that results from in vivo models are more relevant for the potential toxicity of CAR T cell treatment, 34 we also used primary human hematopoietic progenitor cells in our in vivo assays. In this model, CD34 + hematopoietic progenitor cells, which were inoculated in a humanized xenografted environment 13, 29, 36 were detectable up to three weeks in all treatment groups.
This three-week evaluation period was sufficient since in the same time frame we also detected the highest level of anti-MM reactivity. Neither the high affinity CAR T cells nor the optimized affinity CAR T cells disturbed the FLI signal from the inoculated CD34 progenitor cells. However, further analyses revealed that the maintenance of the CD38 + progenitor compartment was achieved only in mice treated with the low affinity CARA4, confirming the low reactivity of our lead candidate towards healthy CD38 + cells.
Finally, while we have been able to optimize the antigen recognition affinity of CARs, we think that these CARs need further evaluation with respect to their signaling requirements as we have tested only
CARs with a 4-1BB co-stimulatory domain. It has recently been shown that that differences in the CAR configuration, either harboring CD28 or 4-1BB co-stimulatory domains, has a large effect on the killing capacity or persistence of CAR T cells. 25, [37] [38] [39] [40] In order to retain a certain pressure on tumor cells, the co-stimulatory domains can shape the activation status of CAR T cells, as well as subsequent proliferation and cytokine production. 25, 37, 41 Accordingly, patient relapses seen in CAR-trials can be caused due to the poor longevity and persistence of CAR T cells. The differentiation status of the CAR T cells (central memory, effector memory or effectors) can somehow predict the in vivo longevity of the CAR T cells. Interestingly, in contrast to previous studies, [14] [15] [16] 34 where no difference in immunophenotype was observed when lowering the affinity of CARs, we found the maintenance of CD38 + CAR T cells when using the lower affinity CARs (Supplemental Fig. S3 ). Furthermore, we observed an apparent higher percentage of naïve and central memory cells in lower affinity CD38-CAR T cells compared to the original CAR028 T cells at the end of production stage, after which the CART cells are generally injected in vivo. Nonetheless, all cells eventually converted to the effector memory phenotype after prolonged in vitro culture, suggesting that the use of other co-stimulatory domains could reveal more optimal designs for low affinity CARs.
In conclusion, our data support the feasibility of the light chain exchange method as a new approach to generate a large panel of scFvs with a wide range of affinities for a TAA epitope. We, here, propose a stepwise rational in vitro and in vivo assessment and scoring of lower affinity CAR T cells in order to identify candidates with a strong tumoricidal function and minimal off-tumor toxicity. In addition to scFv affinity, future studies should include other aspects of the CAR design such as the costimulatory moieties and the targeting of different epitopes in order to achieve optimal selective CAR T cell functionality. 
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